KEI Comments to the NIH on Exclusive License to Lysin Therapeutics

On September 24, 2025, Knowledge Ecology International submitted comments to the NIH regarding the “Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers” (90 FR 43617) to Lysin Therapeutics. Although the… Continue Reading

WHO IGWG3 – KEI’s statement at opening, focuses on transparency, technology transfer and pricing of products, WHO pathogen access and benefit sharing system (PABS) negotiations

On Monday, 3 November 2025, Knowledge Ecology International (KEI) delivered the following intervention at the Third meeting of the open-ended Intergovernmental Working Group on the WHO Pandemic Agreement. Given the significant attacks on the WHO and the importance of restoring… Continue Reading

Table top simulations and licensing proposals round out country submissions on pathogen access and benefit sharing

On 20 May 2025, the World Health Assembly (WHA) adopted the WHO Pandemic Agreement “pursuant to Article 19 of the Constitution of the World Health Organization” through resolution WHA78.1. While achieving consensus on a number of fronts including pandemic prevention… Continue Reading

KEI Submits FOIA Regarding FDA Orphan Products Grant Program

On July 28, 2025, Knowledge Ecology International (KEI) submitted a Freedom of Information Act request for records concerning the Food and Drug Administration (FDA) Orphan Products Grant Program. The program (administered by the FDA’s Office of Orphan Products Development (OOPD))… Continue Reading